CDC7 and small cell lung carcinoma: The CDC7 inhibitor, Simurosertib, has demonstrated safety in early clinical trials, and although it exhibited limited efficacy for several advanced solid tumors [112,113], specific approaches for transformed or de novo SCLC have yet to be explored.